Find the right fit for you - faster
Get tailored insights about working at Thynk Capital in one quick step.
Thynk Capital Snapshot
Focused on early-stage Therapeutics, Healthcare and Technology companies. Thynk Capital provides early stage companies with capital and critical value-added resources to help optimize performance and increase enterprise value, while seeking to provide above market returns to our limited partners. We work collaboratively with our portfolio companies to increase operational efficiencies, strengthen and empower management teams, and build strategic roadmaps for healthy growth and impactful offerings to large markets.
Thynk Capital possess a historical investment performance in the top 1% of venture capital, we are now expanding our investments in early stage pharma and biotech companies focused on extending HealthSpan and major diseases of Aging including Alzheimer’s, Dementia, Kidney Disease, Cancer, Cardiovascular, Diabetes, Frailty, and Rare Disease which affect over 25% of the population and growing at 10% per year.
“40%–70% of total gains were claimed by new and emerging managers, a clear signal to investors to maintain more constant exposure to this cohort……the widely held belief that 90% of venture industry performance is generated by just the top 10 firms is a catchy but unsupported claim that may lead investors to miss attractive opportunities with managers that can provide exposure to substantial value creation.”
– Cambridge Associates Research Note November 2015: Venture Capital Disrupts Itself: Breaking the Concentration Curse.
Thynk Capital possess a historical investment performance in the top 1% of venture capital, we are now expanding our investments in early stage pharma and biotech companies focused on extending HealthSpan and major diseases of Aging including Alzheimer’s, Dementia, Kidney Disease, Cancer, Cardiovascular, Diabetes, Frailty, and Rare Disease which affect over 25% of the population and growing at 10% per year.
“40%–70% of total gains were claimed by new and emerging managers, a clear signal to investors to maintain more constant exposure to this cohort……the widely held belief that 90% of venture industry performance is generated by just the top 10 firms is a catchy but unsupported claim that may lead investors to miss attractive opportunities with managers that can provide exposure to substantial value creation.”
– Cambridge Associates Research Note November 2015: Venture Capital Disrupts Itself: Breaking the Concentration Curse.
